Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aspira Womens Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aspira Womens Health's regulatory disclosures and financial reporting.
John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.
Aspira Women's Health Inc. filed a Form D reporting a Regulation D offering under Rule 506(b). The company stated a $2,950,000 total offering size and reports $2,950,000 sold with $0 remaining, indicating the offering has been fully sold. The first sale date is listed as 2025-09-16. The securities offered include equity, options/warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. The filing lists 19 investors to date, indicates the offering will not last more than one year, and shows $0 in sales commissions and finders' fees. The company disclosed $0 of proceeds paid to named executive officers, directors or promoters. The Form D was signed by Michael Buhle, Chief Executive Officer, on 2025-09-18.
FAQ
What is the current stock price of Aspira Womens Health (AWHL)?
What is the market cap of Aspira Womens Health (AWHL)?
